Discovery ofN-(4-Aminobutyl)-N'-(2-methoxyethyl)guanidine as the First Selective, Nonamino Acid, Catalytic Site Inhibitor of Human Dimethylarginine Dimethylaminohydrolase-1 (hDDAH-1).Lunk, I., Litty, F.A., Hennig, S., Vetter, I.R., Kotthaus, J., Altmann, K.S., Ott, G., Havemeyer, A., Carillo Garcia, C., Clement, B., Schade, D.
(2020) J.Med.Chem. 63: 425-432
- PubMed: 31841335
- DOI: 10.1021/acs.jmedchem.9b01230
- Primary Citation of Related Structures:
- PubMed Abstract:
<i>N </i>-(4-aminobutyl)- <i>N' </i>-(2-methoxyethyl)guanidine ( <b>8a </b>) is as a potent inhibitor targeting the <b>h </b>DDAH-1 active site (K <sub>i </sub> = 18 µM) and derived from a series of guanidine- and amidine-based inhibitors. Its non- ...
N -(4-aminobutyl)- N' -(2-methoxyethyl)guanidine ( 8a ) is as a potent inhibitor targeting the h DDAH-1 active site (K i = 18 µM) and derived from a series of guanidine- and amidine-based inhibitors. Its non-amino acid nature leads to high selectivities towards other enzymes of the nitric oxide-modulating system. Crystallographic data of 8a -bound h DDAH-1 illuminated a unique binding mode. Together with its developed N -hydroxyguanidine prodrug 11 , 8a will serve as a most widely applicable, currently available pharmacological tool to target DDAH-1-associated diseases.